Skip to main content
. Author manuscript; available in PMC: 2021 Feb 1.
Published in final edited form as: Cancer Epidemiol. 2019 Dec 5;64:101652. doi: 10.1016/j.canep.2019.101652

Table 4.

Comparison of hormone therapy information in the registry and the claims

Claims No, CCR No Claims Yes, CCR No Claims No, CCR Yes Claims Yes, CCR Yes Sensitivity PPV Kappa % agreement
All breast a
12 mo 331 105 91 213 67.0 (61.8, 72.2) 70.1 (64.9, 75.2) 45.7 (39.2, 52.2) 74%
6 mo 404 32 218 86 72.9 (64.9, 80.9) 28.3 (23.2, 33.4) 23.1 (17.0, 29.2) 66%
ER positive breast b
12 mo 68 94 82 204 68.5 (63.2, 73.7) 71.3 (66.1, 76.6) 13.5 (4.2, 22.9) 61%
6 mo 133 29 201 85 74.6 (66.6, 82.6) 29.7 (24.4, 35.0) 9.6 (3.1, 16.2) 49%
a

Excludes those with missing ER status (N=142) or missing hormone therapy information from the registry (N=60)

b

Excludes those missing hormone information from the registry (N=49)